THE LANCET, Vol 355, February 26, 2000 George Perry, Akihiko Nunomura, Arun K Raina, Mark A Smith View Poster Post navigationPreviousPrevious post:Neuroactive neurosteroids as endogenous effectors for the sigma1 (σ1) receptor: Pharmacological evidence and therapeutic opportunities.NextNext post:Sigma-1 receptor ligand 4-phenyl-1-(4-phenylbutyl)-piperidine affords neuroprotection from focal ischemia with prolonged reperfusion.Related PostsAnavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett SyndromeJuly 31, 2019Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for the Treatment of Rett SyndromeJuly 29, 2019Anavex Life Sciences to Present at the 30th Annual ROTH ConferenceMarch 9, 2018Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT)March 7, 2018
Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett SyndromeJuly 31, 2019
Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for the Treatment of Rett SyndromeJuly 29, 2019
Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT)March 7, 2018
